• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

    5/30/25 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care
    Get the next $PSTV alert in real time by email

    Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness

    HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the first quarter ended March 31, 2025, and provides an overview of recent and upcoming business highlights.

    "We improved our cash position in the first quarter as a result of both a financing and grant support," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "With the additional cash and further anticipated grant support in 2025, we are well positioned to make solid progress in our 2 key business goals: enrollment in our REYOBIQ™ CNS cancer radiotherapeutic clinical trials and the planned launch of the CNSide® cerebral spinal fluid (CSF) assay platform."

    Q1 2025 & RECENT HIGHLIGHTS AND MILESTONES

    Corporate

    • Raised gross proceeds of $15 million in a private placement financing – along with a $2.0 million grant award advance from the Company's existing grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to accelerate development of REYOBIQ for our leptomeningeal metastases (LM) program.
    • Added industry veteran Kyle Guse to the Board of Directors – Mr. Guse brings 30 years of professional experience in multiple executive roles, including as a Chief Financial Officer and a General Counsel of innovative companies.
    • Strengthened management team with addition of Dr. Michael Rosol as Chief Development Officer – Dr. Rosol will lead the Company's clinical, pre-clinical, and biomarker development activities.

    REYOBIQ™ Clinical Trials

    • Presented updated interim data on its lead compound REYOBIQ™ at the Nuclear Medicine and Neuro-oncology conference held May 9-10, 2025 in Vienna, Austria that highlighted the safety and clinical benefit of REYOBIQ™ in patients with LM.
    • Published Phase 1 clinical trial results for REYOBIQ™ in peer-reviewed publication Nature Communications, demonstrating safety and potential efficacy in treating recurrent glioblastoma (GBM), with patients receiving a radiation dose >100 Gy achieving a median overall survival of 17 months, more than double the standard of care. Additional details can be found here.
    • Completed ReSPECT-LM Phase 1 single dose administration trial and determined the maximum tolerated and recommended Phase 2 dose. Additional details can be found here.
    • Granted U.S. FDA Orphan Drug Designation for REYOBIQ™ for the treatment of LM in patients with lung cancer.
    • Received U.S. FDA conditional agreement for the proprietary name REYOBIQ™ for the Company's lead radiotherapeutic, rhenium Re186 obisbemeda.

    CNSide™ CSF Assay Platform

    • Strengthened management team with key leadership appointments:
      • Russell Bradley as President and General Manager of Plus Therapeutics' wholly owned subsidiary, CNSide Diagnostics, LLC ("CNSide Diagnostics") - Mr. Bradley provides leadership to CNSide Diagnostics with an immediate focus on commercialization of the CSF assay platform.
      • Dr. Jonathan Stein as Medical Director, CNSide Diagnostics - Dr. Stein provides technical leadership to support the CNSide™ CSF assay platform.

    Q1 2025 FINANCIAL RESULTS

    • The Company's cash balance was $9.9 million at March 31, 2025 compared to $0.1 million at December 31, 2024.
    • The Company recognized $1.1 million in grant revenue in the first quarter of 2025 compared to $1.7 million in in the first quarter of 2024, which represents CPRIT's share of the costs incurred for our REYOBIQ™ platform advancement for the treatment of patients with LM.
    • Total operating loss for the first quarter of 2025 was $3.5 million compared to $3.3 million in the same period of 2024. The increase is primarily due to increased legal fees.
    • Net loss for first quarter of 2025 was $17.4 million, or $(1.19) per share, compared to a net loss of $3.3 million, or $(0.75) per share, for the same period the prior year.

    About Plus Therapeutics®

    Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.



    About REYOBIQ™ (rhenium 186re obisbemeda)

    REYOBIQ™ (rhenium 186re obisbemeda) is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. REYOBIQ™ has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. REYOBIQ is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).

    About CNSide Diagnostic, LLC

    CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide™, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide™ CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases. The Company is planning to commercialize CNSide™ in the U.S. in 2025.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as "expect" "potential," "anticipating," "planning" and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

    These statements include, without limitation, statements regarding the potential promise of REYOBIQ™, expectations as to the Company's future performance, including the next steps in developing the Company's product candidates; the Company's clinical trials, including statements regarding the timing and characteristics of the ReSPECT-LM single dose and multi-dose clinical trials; the continued evaluation of REYOBIQ™ including through evaluations in additional patient cohorts; and expectations regarding receipt of grant funds.

    The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the Company's ability to maintain the listing of its common stock on Nasdaq; risks related to a halt in trading or delisting of the Company's common stock on Nasdaq; the early stage of the Company's product candidates and therapies; the results of the Company's research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company's liquidity and capital resources and its ability to raise additional cash; the outcome of the Company's partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company's clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company's operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics' business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics' annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC's website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

    Investor Contact



    CORE IR

    [email protected] 

    PLUS THERAPEUTICS, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (UNAUDITED)

    (in thousands, except share and par value data)
        
      March 31, 2025  December 31, 2024 
    Assets      
    Current assets:      
    Cash and cash equivalents $9,867  $76 
    Investments  —   3,530 
    Grant receivable  —   571 
    Other current assets  1,001   1,082 
    Total current assets  10,868   5,259 
           
    Property and equipment, net  324   448 
    Operating lease right-use-of assets  38   73 
    Goodwill  372   372 
    Intangible assets, net  435   469 
    Other assets  19   12 
    Total assets $12,056  $6,633 
    Liabilities and Stockholders' Equity      
    Current liabilities:      
    Accounts payable and accrued expenses $9,222  $11,288 
    Operating lease liability  40   44 
    Deferred grant liability  1,297   927 
    Line of credit  —   3,292 
    Total current liabilities  10,559   15,551 
           
    Warrant liability  25,138   — 
    Noncurrent operating lease liability  —   31 
    Total liabilities  35,697   15,582 
           
    Stockholders' equity (deficit):      
    Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively  —   — 
    Common stock, $0.001 par value; 100,000,000 shares authorized; 17,258,051 and 16,999,626 issued and outstanding at March 31, 2025, and 6,154,758 issued and 5,896,333 outstanding as of December 31, 2024, respectively  17   6 
    Treasury stock (at cost, 258,425 shares as of March 31, 2025 and December 31, 2024, respectively)  (500)  (500)
    Additional paid-in capital  487,722   485,024 
    Accumulated deficit  (510,880)  (493,479)
    Total stockholders' equity (deficit)  (23,641)  (8,949)
    Total liabilities and stockholders' equity (deficit) $12,056  $6,633 
             



    PLUS THERAPEUTICS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (UNAUDITED)

    (in thousands, except share and per share data)
        
      For the Three Months Ended March 31, 
      2025  2024 
    Grant revenue $1,059  $1,677 
           
    Operating expenses:      
    Research and development  1,756   2,763 
    General and administrative  2,839   2,213 
    Total operating expenses  4,595   4,976 
    Operating loss  (3,536)  (3,299)
           
    Other income (expense):      
    Interest income  1   72 
    Interest expense  (548)  (34)
    Financing expenses  (3,211)  — 
    Warrant issuance costs  (964)  — 
    Change in fair value of derivative instruments  (9,143)  — 
    Total other expense  (13,865)  38 
    Net loss $(17,401) $(3,261)
           
    Net loss per share, basic and diluted $(1.19) $(0.75)
           
    Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders  14,566,724   4,321,731 
             



    PLUS THERAPEUTICS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (UNAUDITED)

    (In thousands)
        
      For the Three Months Ended March 31, 
      2025  2024 
    Cash flows used in operating activities:      
    Net loss $(17,401) $(3,261)
    Adjustments to reconcile net loss to net cash used in operating activities:      
    Depreciation and amortization  146   155 
    Amortization of deferred financing costs and debt discount  —   16 
    Share-based compensation expense  148   146 
    Noncash financing expenses  3,211   — 
    Change in fair value of derivative instruments  9,143   — 
    Accretion of discount on short-term investments  —   1 
    Reduction in the carrying amount of operating lease right-of-use assets  35   31 
    Loss on disposal of property and equipment  (16)  — 
    Increases (decreases) in cash caused by changes in operating assets and liabilities:      
    Grant receivable  571   — 
    Other current assets  74   150 
    Accounts payable and accrued expenses  (2,418)  (43)
    Change in operating lease liabilities  (35)  (31)
    Deferred grant liability  370   (1,677)
    Net cash used in operating activities  (6,172)  (4,513)
           
    Cash flows used in investing activities:      
    Purchases of property and equipment  (3)  (40)
    Proceeds from sale of property and equipment  30   — 
    Redemption of short-term investments  3,531   (324)
    Net cash provided by (used in) investing activities  3,558   (364)
           
    Cash flows used in/provided by financing activities:      
    Principal payments of term loan obligation  —   (402)
    Repayment of line of credit facility  (3,292)  — 
    Repayment of notes payable  (3,703)  — 
    Issuance of notes payable and warrants  3,738    
    Proceeds from exercise of warrants  882    
    Purchase of treasury stock  —   (374)
    Proceeds from sale of common stock, prefunded warrants and warrants, net  14,780   — 
    Net cash provided by (used in) financing activities  12,405   (776)
    Net increase (decrease) in cash and cash equivalents  9,791   (5,653)
    Cash and cash equivalents at beginning of period  76   8,554 
    Cash and cash equivalents at end of period $9,867  $2,901 
           
    Supplemental disclosure of cash flows information:      
    Cash paid during period for:      
    Interest $539  $23 
    Supplemental schedule of non-cash investing and financing activities:      
    Exchange of warrants for notes payable $3,694  $— 
    Redemption of notes by issuance of common stock, prefunded warrants and warrants $3,512  $— 
    Unpaid offering cost $202  $141 


    Primary Logo

    Get the next $PSTV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSTV

    DatePrice TargetRatingAnalyst
    3/17/2025$9.00Buy
    D. Boral Capital
    More analyst ratings

    $PSTV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

      Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the first quarter ended March 31, 2025, and provides an overview of recent and upcoming business highlights. "We improved our cash position in the first quarter as a result of both a financing and grant support," said Marc H. Hedrick, M.D., Plus Therapeutics President

      5/30/25 4:15:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

      HOUSTON, May 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company") today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the delayed filing of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the "Quarterly Report"). The Nasdaq Listing Rule requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the "SEC"). This notification has no immediate effect on the listing of the Company's securities on Nasdaq. Nasdaq has

      5/23/25 4:15:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

      Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data presented at the 2025 Nuclear Medicine and Neurooncology Conference HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the presentation of new data on its lead drug REYOBIQ™ (rhenium Re186 obisbemeda) during both an oral presentation and a poster presented at the Nuclear Medicine and

      5/14/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Financials

    Live finance-specific insights

    See more
    • Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights. "Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "The rece

      3/27/25 4:05:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

      HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference Call Date/Time:Thursday, March 27, 2025 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/5r5hkcqqDial-in

      3/19/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReSPECT-GBM Trial Data at the 2024 Congress of Neurological Surgeons Annual Conference Established Radiotherapeutic Manufacturing Partnership with SpectronRx to meet late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) ca

      11/14/24 4:15:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PLUS THERAPEUTICS Inc.

      SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      6/5/24 7:26:01 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

      SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      2/13/23 3:25:03 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

      SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      2/11/22 7:53:23 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Plus Therapeutics with a new price target

      D. Boral Capital initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $9.00

      3/17/25 7:41:57 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • HC Wainwright initiated coverage on Plus Therapeutics

      HC Wainwright initiated coverage of Plus Therapeutics with a rating of Buy

      2/11/21 7:44:56 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. initiated coverage on Plus Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $7.00

      2/11/21 6:52:36 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    SEC Filings

    See more

    $PSTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      5/30/25 4:20:16 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by PLUS THERAPEUTICS Inc.

      10-Q - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      5/30/25 4:15:24 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      5/23/25 4:22:57 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Director Hawkins Richard J bought $5,996 worth of shares (4,000 units at $1.50), increasing direct ownership by 36% to 15,188 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/17/24 7:00:04 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Director Hawkins Richard J bought $8,512 worth of shares (6,285 units at $1.35), increasing direct ownership by 128% to 11,188 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/16/24 7:00:03 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Director Petersen Greg bought $16,875 worth of shares (12,500 units at $1.35), increasing direct ownership by 34% to 48,921 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/13/24 6:04:12 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Leadership Updates

    Live Leadership Updates

    See more
    • Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

      HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. "Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus' board of directors," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Furthermore, in his

      4/23/25 8:00:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

      AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the appointment of Michael Rosol, Ph.D., as Chief Development Officer. Dr. Rosol will lead the company's clinical, pre-clinical, and biomarker development activities. "Plus is at an inflection point in our clinical development as we move from mid-stage to pivotal trials next year," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Mike's background in oncology and radiotherapeutic

      2/20/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

      Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the appointment of Dr. Greg Fuller a

      6/7/24 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Clowes Howard

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:10 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Hawkins Richard J

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:11 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Petersen Greg

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:03 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care